Structure Therapeutics Inc.
About Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$141.2M
- Total assets
- $1.6B
- Market cap
- $2.7B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $176.6M
- Operating income
- -$176.6M
- Income tax
- $515.0K
- Net income
- -$141.2M
- EPS (basic)
- $-0.80
- EPS (diluted)
- $-0.80
Balance sheet
- Total assets
- $1.6B
- Current assets
- $1.6B
- Total liabilities
- $67.5M
- Current liabilities
- $63.3M
- Shareholders’ equity
- $1.5B
Cash flow
- Operating cash flow
- -$222.2M
- Investing cash flow
- $89.8M
- Financing cash flow
- $762.5M
- Net cash flow
- $630.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.7B
- EPS (diluted)
- $-0.8
- Shares outstanding
- 70.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 3, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $141.2M.
- Trading 60% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Structure Therapeutics Inc..
Write a review
News about Structure Therapeutics Inc.
News & sentiment via Polygon.io
